logo
Sibson to take Mitchell's tax increment district complaints before SD audit committee

Sibson to take Mitchell's tax increment district complaints before SD audit committee

Yahoo2 days ago

May 30—MITCHELL — Mitchell resident Steve Sibson is taking Mitchell's increment tax districts before a state legislative committee, raising concerns that the number of tax districts in the city lacks proper scrutiny and may not follow state approval procedures.
On May 19, Sibson gave the city council an update on his conversations with the South Dakota Department of Revenue, particularly with regard to TID No. 41.
According to previous discussions, increment districts no longer have to be pre-approved by the revenue department before going before a city council or county commission. However, Sibson shared that this was not the case, and that Mitchell was receiving special treatment because of the volume of TIDs the city has.
"When I brought up the push back on that requirement for a pre-approved submission as to classification type, I was told that is still in place," Sibson said. "It seems like the Department of Revenue is rubber stamping what we're doing here."
The Mitchell Republic reached out to the South Dakota Department of Revenue to confirm Sibson's statements to the council, but the department had not responded by the time this article was published.
During its May 19 regular meeting, the Mitchell City Council approved a developer agreement for Tax Increment District (TID) No. 41 for affordable housing and street construction, and also approved a developer agreement for TID No. 42 to expand the Dale's A1 Transmission service building on South Burr Street.
The council previously approved the creation and project plans of these tax districts on May 5.
TID No. 41 includes two projects, which Sibson took as an issue to the revenue department.
In particular, the TID No. 41 agreement lays out what will happen to increment-generated tax funds once the affordable housing units are completed, specifically the construction of Mattie Street.
Sibson raised concerns with the revenue department that property owners along Mattie Street, some of whom are outside of Mitchell city limits in Davison County, will be taxed to complete Mattie Street.
The city's response is that they don't know if that will happen yet.
City Attorney Justin Johnson told the Mitchell Republic that the city won't know how much of the Mattie Street construction can be supported by TID No. 41 until the apartments have been built and the property values have been established.
In the coming years, if the council decides to construct Mattie Street without enough support from TID No. 41, then the rest of the project will have to be paid for somehow, according to Johnson.
"It's possible that part of it could be done by special assessment, which neighboring properties would be responsible for," Johnson said.
If TID No. 41 covers part of the cost of constructing Mattie Street, property owners along Mattie Street would likely be paying less than if there was no tax district at all, Johnson noted.
If there were no tax district funds available and the council decided to move forward, assessments for those properties along Mattie Street would cover the whole construction cost of Mattie Street.
In other words, if TID No. 41 doesn't pay for all of the construction costs and the city doesn't pay for it out of general funds, Mattie Street property owners are on the hook to complete the road.
The boundaries of Mattie Street are within the Mitchell city limits. However, only the right of way for the street is within the city limits while the properties on either side of Mattie Street on the south side are outside of the city limits.
A tax increment is only generated from property within the boundaries of the TID, but no tax funds will be generated from the street itself, which is a right-of-way, and therefore tax-exempt, according to Mitchell Finance Officer Michelle Bathke.
If a special assessment were levied against property owners, then even those property owners outside of city limits would be liable for paying a share of the burden to finish construction of Mattie Street to East Havens Avenue.
In addition to the city potentially raising a tax levy against individual property owners along Mattie Street, the status of TID No. 41 may result in a special levy to maintain tax funds for the Mitchell School District.
According to Sibson, the city of Brookings passed a TID that required a special assessment in the amount of $470,000, which taxpayers had to pay. Sibson raised concern with Davison County auditors that the same thing could happen in Mitchell.
TID No. 41 was passed to fund Paul Groeneweg's Woods Apartments, a proposed 70-unit complex with two-and-three-bedroom apartments across 12 buildings, which Sibson found no fault with. It is estimated that the developer's infrastructure will be covered by TID No. 41 at an estimated $2.28 million in tax funds.
However, Sibson had problems with the city including street construction as a separate project on the same TID. A violation of TID rules, according to Sibson's research.
This TID is unique in that it also has a plan to construct the area of Mattie Street south of First Avenue and north of East Havens Avenue, including intersections, with a projected $2.02 million in tax funds.
This is not the first TID to seek to complete a portion of Mattie Street. In 2012, TID No. 17 was introduced to cover the construction cost of a portion of Mattie Street, but ultimately failed to complete the task.
TID No. 17 was paid off in nine years and resulted in $12,849,130 of assessed value growth when it was dissolved, according to City Administrator Stephanie Ellwein.
At the time TID No. 17 was approved in 2012, it was estimated that $200,000 would be raised toward the construction of roughly 450 feet of Mattie Street. TID No. 17 included five phases, with the last phase being Mattie Street's road, sewer and water installation. This would have connected the area of Mattie Street between East Birch Avenue and Charles Avenue, but would not have connected to East Havens Avenue.
TIDs have four kinds of classifications with the Department of Revenue — local, industrial, economic development and affordable housing.
Previously, Sibson told the council he was concerned about the Mattie Street project, that if it included a local TID classification then it would be denied at the state level for tax reimbursement for the school district.
In a local TID, projects usually benefit the local government instead of having a regional or statewide benefit,
according to the Department of Revenue.
Local TID projects are subject to a special levy protection for school districts by the county auditor. This means that even if a local TID is passed, it may result in additional levies on all property in the Mitchell School District, not just those properties within the TID boundaries.
"This is not just about the city of Mitchell. This is statewide concerning how our property taxes are being impacted by things like this," Sibson told the council.
A revenue department employee offered Sibson the opinion to refer TID No. 41 to a vote of the people, which Sibson told the council he would not do.
Instead, Sibson is tackling the issue at the state level by addressing legislative committees directly. Sibson said he would take the issue to the South Dakota Government Operations and Audit Committee, which is made up of a mix of senators and representatives.
"I just want to give the city council a heads up that if some things come up at the state level about this particular project, I don't want it to be me giving the city of Mitchell a black eye for doing something that's going on statewide," Sibson said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Johnson to Senate fiscal hawks: Will take ‘more than a flip of a switch' to fix US finance
Johnson to Senate fiscal hawks: Will take ‘more than a flip of a switch' to fix US finance

Yahoo

timean hour ago

  • Yahoo

Johnson to Senate fiscal hawks: Will take ‘more than a flip of a switch' to fix US finance

House Speaker Mike Johnson (R-La.) defended the House-passed spending package in an interview that aired Sunday while lauding the bill's unprecedented cuts. President Trump has endorsed the legislation, which would add $4 trillion to the national debt. 'We have $36 trillion in federal debt. But it's important to remember that we did not get into that financial situation overnight. It took many decades … It's going to take more than a flip of a switch to turn it around,' Johnson said during an appearance on John Catsimatidis's radio show, 'Cats Roundtable' on WABC 770 AM. Critics, including Elon Musk, have slammed the bill for the debt ceiling increase, alleging it 'undermines' federal spending reductions made by the Department of Government Efficiency. However, Johnson remains confident that the legislation will help the country shift away from past transgressions. 'This is a dramatic shift in the right direction. And it's just the beginning,' Johnson said. 'We're going to have more of this in the Republican Congress under President Trump's leadership to get us out of the debt mess that we're in.' Republicans are pushing to have the text approved in the Senate prior to the Fourth of July, although they have received pushback from Democrats over Medicaid reforms set to leave millions without access to healthcare. 'Everybody, take a deep breath. Look at the legislation. You're going to find that you're very much in favor of what we're doing here,' Johnson told Catsimatidis. 'If we do not clean the system up, if we do not eliminate fraud, waste, and abuse, these programs will become insolvent, and they will not be there for the people who desperately need and deserve it. We're doing the right thing here,' he added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Yahoo

time3 hours ago

  • Yahoo

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio

Johnson to Senate fiscal hawks: Will take ‘more than a flip of a switch' to fix US finance
Johnson to Senate fiscal hawks: Will take ‘more than a flip of a switch' to fix US finance

The Hill

time4 hours ago

  • The Hill

Johnson to Senate fiscal hawks: Will take ‘more than a flip of a switch' to fix US finance

House Speaker Mike Johnson (R-La.) defended the House-passed spending package in an interview that aired Sunday while lauding the bill's unprecedented cuts. President Trump has endorsed the legislation, which would add $4 trillion to the national debt. 'We have $36 trillion in federal debt. But it's important to remember that we did not get into that financial situation overnight. It took many decades … It's going to take more than a flip of a switch to turn it around,' Johnson said during an appearance on John Catsimatidis's radio show, 'Cats Roundtable' on WABC 770 AM. Critics, including Elon Musk, have slammed the bill for the debt ceiling increase, alleging it 'undermines' federal spending reductions made by the Department of Government Efficiency. However, Johnson remains confident that the legislation will help the country shift away from past transgressions. 'This is a dramatic shift in the right direction. And it's just the beginning,' Johnson said. 'We're going to have more of this in the Republican Congress under President Trump's leadership to get us out of the debt mess that we're in.' Republicans are pushing to have the text approved in the Senate prior to the Fourth of July, although they have received pushback from Democrats over Medicaid reforms set to leave millions without access to healthcare. 'Everybody, take a deep breath. Look at the legislation. You're going to find that you're very much in favor of what we're doing here,' Johnson told Catsimatidis. 'If we do not clean the system up, if we do not eliminate fraud, waste, and abuse, these programs will become insolvent, and they will not be there for the people who desperately need and deserve it. We're doing the right thing here,' he added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store